{"nctId":"NCT02290509","briefTitle":"Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age","startDateStruct":{"date":"2014-10"},"conditions":["Influenza"],"count":1350,"armGroups":[{"label":"Flublok Quadrivalent Influenza Vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: Flublok Quadrivalent"]},{"label":"Inactivated Influenza Vaccine (IIV4)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Inactivated Influenza Vaccine (IIV4)"]}],"interventions":[{"name":"Flublok Quadrivalent","otherNames":[]},{"name":"Inactivated Influenza Vaccine (IIV4)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ambulatory, in good health or medically stable\n* Able to understand and comply with planned study procedures\n* Provide written informed consent\n* Negative urine pregnancy test within 24 hours prior to vaccination (women of child-bearing potential)\n\nExclusion Criteria:\n\n* Prior serious or severe reaction to influenza vaccine\n* Known contraindication to either study vaccine\n* Receipt of any other influenza vaccine within 180 days prior to enrollment\n* Plan to receive another licensed influenza or other vaccine during the duration of this study\n* Receipt of any significant new diagnosis, medication (licensed or investigational), or licensed vaccine within 30 days prior to enrollment in this study\n* Underlying disease or therapeutic intervention that might adversely affect the immune response\n* Plans to participate in any investigation involving an investigational product during this study.\n* Pregnant, lactating or planning to become pregnant within 30 days of study vaccine.\n* Any clinical or social circumstance that in the opinion of the investigator could interfere with compliance with study procedures or interfere with the interpretation","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine","description":"Seroconversion is defined as: Either a pre vaccination titer \\< 10 (1/dil) and a post vaccination titer ≥ 40 (1/dil), or a pre vaccination titer ≥ 10 (1/dil) and a ≥ 4 fold increase in post vaccination titer at Day 28 after the final vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"63.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"57.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null},{"groupId":"OG001","value":"60.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null},{"groupId":"OG001","value":"58.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Systemic and Injection Site Reactogenicity","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"510","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"339","spread":null},{"groupId":"OG001","value":"119","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs) and Medically-attended Adverse Events (MAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers of Antibodies to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine","description":"Immunogenicity will be evaluated prior to vaccination and at 28 days after vaccination using the hemagglutination inhibition (HAI) technique. For each influenza vaccine strain, pre and post vaccination geometric mean titers (GMTs) were calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"502","spread":null},{"groupId":"OG001","value":"407","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"757","spread":null},{"groupId":"OG001","value":"385","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":998},"commonTop":["Headache","Nasophayngitis","Cough","Upper respiratory tract infection","Sinusitis"]}}}